(Nasdaq: INBS) Reported Record Revenue Growth In Q2 (Low Float Under 2Mn Shares)

Next up on our radar... Here's a past champ firmly sitting in our crosshairs.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: INBS) Reported Record Revenue Growth In Q2 (Low Float Under 2Mn Shares) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* February 25th Greetings, Friend! Next up on our radar... Here's a past champ firmly sitting in our crosshairs. Brought into focus this past summer, it originally popped from an open of $1.28 to a high of $2.25 in the short term. That run of approximately 74% showed how explosive this under-the-radar Nasdaq profile can be. Even better, I released recently this idea in December. From an open on the 18th of $6.23, it surged to a high of $24.90 on January 12th for a move of approx. 299% short term. Now, as key technical indicators hover around SEVERLY oversold levels (as of close Tuesday), a healthy reversal could be approaching on the horizon. And with this profile's float of fewer than 2Mn shares meaning volatility potential could be significantly heightened on daily basis, this Nasdaq profile now tops our watchlist: Intelligent Bio Solutions Inc. (Nasdaq: INBS) Intelligent Bio Solutions Inc. is rapidly emerging as a leader in the medical technology sector, pioneering non-invasive, real-time point-of-care testing solutions that are reshaping how drug screening and diagnostics are conducted worldwide. With a focus on pain-free, accessible, and accurate testing, the company is positioned at the forefront of a global movement toward more humane and efficient healthcare technologies. Company Overview Founded in 2016 and headquartered in New York, Intelligent Bio Solutions Inc. is committed to leveraging advanced technology to develop transformative solutions that improve quality of life. The company’s mission is to redefine the approach to testing by delivering pain-free, accessible solutions that drive transformative change across healthcare and workplace safety. Core Technologies and Products Intelligent Fingerprinting Drug Testing Solution At the heart of INBS’s innovation is the Intelligent Fingerprinting Drug Testing Solution. This system utilizes a patented technology that analyzes sweat collected from the fingertips to detect recent drug use-including cann-a-bis, co-caine, o-piate-s, and me-thamp-heta-mine-within the preceding 16–24 hours. The process is non-invasive, requiring less than a minute for sample collection and delivering results in under ten minutes. Key advantages include: Dignified, Non-Invasive Collection: No need for blood, urine, or saliva samples, reducing discomfort and privacy concerns. Rapid Results: Enables timely decision-making in workplace, clinical, and law enforcement settings. Portability and Ease of Use: Designed for use in the field, workplaces, and clinics, with minimal training required. Hygienic and Cost-Effective: Reduces biohazard risks and maintenance costs, with annual calibration sufficing for ongoing use. Regulatory Milestones And U.S. Market Entry A significant milestone was achieved with the submission of the FDA 510(k) pre-market notification for the Intelligent Fingerprinting Drug Screening System in December 2024. The company’s clinical studies have demonstrated high sensitivity, specificity, and usability, with performance data showing 94.1% accuracy and pharmacokinetic studies confirming the reliability of fingerprint sweat as a matrix for drug detection. INBS is on track for a planned expansion into the multi-Bn dollar U.S. market in 2026, targeting a region that accounts for approximately 28% of the global drug screening market. The rising rates of drug positivity in the U.S. workforce-particularly in safety-sensitive industries-underscore the urgent need for effective, rapid, and non-invasive testing solutions like those offered by INBS. Intellectual Property and Competitive Position INBS’s technology is protected by a robust intellectual property portfolio, including six U.S. patents covering the lateral flow test strip, sample collection cartridge, cartridge housing, and buffer clip design. This IP protection strengthens the company’s competitive position as it prepares for broader commercialization and future product development. Market Opp. And Future Outlook Why Take A Closer Look? Intelligent Bio Solutions Inc. stands out for several compelling reasons: Innovative, Patented Technology: Non-invasive, rapid, and highly accurate testing solutions with strong IP protection. Proven Market Acceptance: Operational in at least 19 countries with a growing base of over 480 customer accounts. Strong Financial Trajectory: Demonstrated revenue and margin growth, with a scalable, recurring revenue model. Strategic Global Expansion: Active in high-growth markets and sectors, with multilingual capabilities and key partnerships. Clear Path to U.S. Market: On track for potential FDA clearance and entry into the world’s largest drug screening market in 2025. Vision for Broader Diagnostics: Versatile biosensor platform poised for future applications in clinical diagnostics. ----- Five (Nasdaq: INBS) Potential Catalysts To Consider #1. A Low Float - INBS has a very low float of roughly 1.59Mn shares. This means volatility potential may be heightened on a daily basis. #2. An Analyst $12 Target - As of February 24th, Ladenburg Thalmann Co. Inc. was reporting a $12 target on INBS. From its closing valuation on Tuesday, that target is suggesting INBS to have over 175% potential upside. #3. Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Bn Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout. Intelligent Bio Solutions Inc. has partnered with Bouygues UK, a subsidiary of multinational construction giant Bouygues Construction, to deploy its fingerprint drug testing technology across 13 UK sites. This collaboration validates the technology’s scalability, cost-efficiency, and superior hygiene standards while aligning with Bouygues’ strong safety culture. Through joint ROI analysis, INBS demonstrated measurable savings and operational advantages, motivating Bouygues to shift from third-party services to in-house testing. The partnership establishes a foundation for broader multinational adoption, highlighting INBS’s expanding footprint in large-scale industrial environments. #4. Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year. Intelligent Bio Solutions Inc. reported a 48% year-over-year revenue increase for its fiscal second quarter, with reader sales soaring 104%. First-half 2026 revenue exceeded $2Mn, marking 36% annual growth. The company’s razor-razorblade sales model—driven by hardware placements and recurring cartridge sales—is fueling sustained pro-fit-ability, with gross pro-fit margins rising to 49%. Supported by $9.4Mn in new capital, INBS’s strong financial position and expanding installed base underscore its growing market demand, operational efficiency, and progress toward U.S. regulatory clearance and commercial expansion. #5. A Potential Healthy Reversal Could Be Approaching For INBS. Technical analysis reveals INBS has several oversold indicators, suggesting a possible reversal setup may be developing. At close on Tuesday, INBS had a 9 and 14-Day Relative Strength Index both below 29% and a 14-Day Raw Stochastic below 12%. These technical levels suggest a profile that may be currently undervalued. ----- Coverage is officially underway again on Intelligent Bio Solutions Inc. (Nasdaq: INBS). Updates will be out soon. Keep your eyes peeled. All the best, Dane James Editor Market Pulse Today Sources: INBS Website INBS Presentation (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 02/25/2026 and ending on 02/25/2026 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid twenty five thousand USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (INBS:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/inbs-qe5ho/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice